| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
|
J Clin Microbiol
|
2001
|
5.28
|
|
2
|
Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?
|
Clin Infect Dis
|
2007
|
4.51
|
|
3
|
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.
|
Antimicrob Agents Chemother
|
2000
|
4.03
|
|
4
|
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
|
J Clin Microbiol
|
1998
|
3.33
|
|
5
|
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
|
Clin Infect Dis
|
2001
|
3.18
|
|
6
|
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).
|
Diagn Microbiol Infect Dis
|
1999
|
3.11
|
|
7
|
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
|
Diagn Microbiol Infect Dis
|
1995
|
2.87
|
|
8
|
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997.
|
Clin Infect Dis
|
1999
|
2.61
|
|
9
|
Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).
|
Clin Microbiol Infect
|
2006
|
2.08
|
|
10
|
Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.
|
Diagn Microbiol Infect Dis
|
1999
|
1.88
|
|
11
|
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.
|
Int J Antimicrob Agents
|
2000
|
1.83
|
|
12
|
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).
|
J Antimicrob Chemother
|
2000
|
1.56
|
|
13
|
Inter-hospital dissemination of glycopeptide-resistant Enterococcus faecalis in Brazil.
|
Clin Microbiol Infect
|
2004
|
1.55
|
|
14
|
An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil.
|
Infect Control Hosp Epidemiol
|
1996
|
1.50
|
|
15
|
Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
|
J Chemother
|
2005
|
1.26
|
|
16
|
Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
|
Diagn Microbiol Infect Dis
|
1999
|
1.21
|
|
17
|
blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program.
|
J Clin Microbiol
|
2006
|
1.16
|
|
18
|
Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
|
Diagn Microbiol Infect Dis
|
2003
|
1.08
|
|
19
|
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
|
Antimicrob Agents Chemother
|
2008
|
1.03
|
|
20
|
Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group.
|
Int J Infect Dis
|
2000
|
1.00
|
|
21
|
Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients.
|
J Clin Microbiol
|
2001
|
0.98
|
|
22
|
Metallo-beta-lactamase IMP-18 is located in a class 1 integron (In96) in a clinical isolate of Pseudomonas aeruginosa from Mexico.
|
Int J Antimicrob Agents
|
2007
|
0.98
|
|
23
|
Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program.
|
Clin Infect Dis
|
2001
|
0.96
|
|
24
|
Screening of antibacterial extracts from plants native to the Brazilian Amazon Rain Forest and Atlantic Forest.
|
Braz J Med Biol Res
|
2004
|
0.91
|
|
25
|
Prevalence and genetic characterization of blaCTX-M among Klebsiella pneumoniae isolates collected in an intensive care unit in Brazil.
|
J Chemother
|
2008
|
0.90
|
|
26
|
Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries.
|
J Chemother
|
2011
|
0.90
|
|
27
|
In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolates.
|
J Chemother
|
1996
|
0.89
|
|
28
|
Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
|
J Chemother
|
2008
|
0.89
|
|
29
|
Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
|
J Chemother
|
2005
|
0.88
|
|
30
|
Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997-98.
|
Clin Microbiol Infect
|
2000
|
0.87
|
|
31
|
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
|
Clin Microbiol Infect
|
2005
|
0.86
|
|
32
|
Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program.
|
J Chemother
|
2004
|
0.86
|
|
33
|
In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals.
|
Braz J Infect Dis
|
2003
|
0.86
|
|
34
|
Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008.
|
J Chemother
|
2010
|
0.85
|
|
35
|
Microbiological and epidemiological characterization of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian tertiary hospital: report from the SENTRY Antimicrobial Surveillance Program.
|
J Chemother
|
2006
|
0.83
|
|
36
|
Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.
|
J Clin Microbiol
|
2004
|
0.83
|
|
37
|
[Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci].
|
Rev Assoc Med Bras
|
1998
|
0.82
|
|
38
|
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
|
J Chemother
|
2010
|
0.80
|
|
39
|
Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening.
|
Infect Dis Clin North Am
|
2000
|
0.80
|
|
40
|
Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998).
|
Diagn Microbiol Infect Dis
|
2000
|
0.79
|
|
41
|
Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000.
|
Braz J Infect Dis
|
2003
|
0.77
|
|
42
|
Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.
|
Clin Microbiol Infect
|
2004
|
0.77
|
|
43
|
Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
|
Clin Microbiol Infect
|
2004
|
0.77
|
|
44
|
Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection.
|
Int J Infect Dis
|
2005
|
0.76
|
|
45
|
In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
|
Braz J Infect Dis
|
2000
|
0.75
|
|
46
|
[In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
|
Rev Assoc Med Bras
|
1997
|
0.75
|
|
47
|
[Sensitivity pattern of 117 clinical isolates of Staphylococcus aureus from 12 hospitals].
|
Rev Assoc Med Bras
|
1998
|
0.75
|
|
48
|
[Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria].
|
Rev Assoc Med Bras
|
1998
|
0.75
|
|
49
|
In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
|
Braz J Infect Dis
|
2003
|
0.75
|
|
50
|
Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.
|
Diagn Microbiol Infect Dis
|
1994
|
0.75
|